{
    "nctId": "NCT03358004",
    "briefTitle": "the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment",
    "officialTitle": "An International, Multicenter, Phase II, Randomized, Parallel-arm Trial Investigating the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment",
    "overallStatus": "TERMINATED",
    "conditions": "Triple Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 4,
    "primaryOutcomeMeasure": "PFS-12 weeks",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female, aged \u2265 18 years old;\n* Eastern Cooperative Oncology Group performance status (ECOG -PS) \u2264 1;\n* Locally advanced or metastatic triple-negative breast cancer, i.e. HER2-negative status and ER and PgR negative status (as per local assessment);\n* Treatment with 1st line chemotherapy (with any drug excepted Bevacizumab-based regimens) as per clinical practice, and non-progressive when the treatment was terminated;\n* No more than 6 cycles of the previous chemotherapy;\n* At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1);\n* Willingness and ability to comply with the study protocol as judged by the Investigator;\n* For women who are not postmenopausal (i.e., \\< 2 years after last menstruation) and who are sexually active: agreement to use an adequate method of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly) during the treatment period and for at least 6 months after the last dose of study drug;\n* Provision of a written informed consent signed prior to enrolment according to ICH/GCP.\n\nExclusion Criteria:\n\n* Previous treatment with vinorelbine or capecitabine;\n* 1st line therapy with a bevacizumab-based regimen;\n* Presence of brain metastases;\n* Any other investigational drug or any anti-cancer treatment (except for radiotherapy, if the treatment field does not include the liver);\n* Inadequate bone marrow, hepatic or renal function including the following:\n\n  1. absolute neutrophils count of \\< 1.5 cells x 109/L, platelet count \\< 100 cells x 109/L, or hemoglobin \\< 8 g/L;\n  2. serum total bilirubin \\>1.5 \u00d7 institution upper limit of normal \\[ULN\\], aspartate aminotransferase and alanine aminotransferase \\>2.5 \u00d7 ULN, or \\>5 \u00d7 ULN for patients with liver metastases, alkaline phosphatase \\>2.5 \u00d7 ULN, or \\>5 \u00d7 ULN for patients with liver metastases, or \\>10 \u00d7 ULN for patients with bone metastases;\n  3. serum creatinine concentration \\>1.5 \u00d7 ULN, creatinine clearance \\<50 mL/min calculated according to Cockcroft-Gault equation, and coagulation parameters international normalized ratio \\>1.5;\n* With the exception of basal cell carcinoma or cervical cancer in situ, history of another malignancy, unless in remission for 5 years or more and judged of negligible potential of relapse;\n* Known dihydropyrimidine dehydrogenase deficiency;\n* Treatment with sorivudine or its chemically related analogues, such as brivudine, within 4 weeks prior to randomization;\n* Evidence of any significant clinical disorder or concurrent illness or laboratory finding that, at the judgment of the Investigator, contra-indicate the inclusion of the patient in the study;\n* Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary study assessment and procedures;\n* Unable to swallow tablets;\n* Previous significant surgical resection of stomach or small bowel\n* Patients requiring long-term oxygen therapy\n* Known hypersensitivity to any excipients of oral vinorelbine, oral capecitabine and to fluoropyrimidine.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}